JP2017521371A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017521371A5 JP2017521371A5 JP2016569722A JP2016569722A JP2017521371A5 JP 2017521371 A5 JP2017521371 A5 JP 2017521371A5 JP 2016569722 A JP2016569722 A JP 2016569722A JP 2016569722 A JP2016569722 A JP 2016569722A JP 2017521371 A5 JP2017521371 A5 JP 2017521371A5
- Authority
- JP
- Japan
- Prior art keywords
- ndc
- moiety
- drug
- spacer
- enzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940079593 drug Drugs 0.000 claims 31
- 239000003814 drug Substances 0.000 claims 31
- 102000004190 Enzymes Human genes 0.000 claims 19
- 108090000790 Enzymes Proteins 0.000 claims 19
- 239000002105 nanoparticle Substances 0.000 claims 19
- 125000005647 linker group Chemical group 0.000 claims 18
- 125000006850 spacer group Chemical group 0.000 claims 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 239000002202 Polyethylene glycol Substances 0.000 claims 9
- 229920001223 polyethylene glycol Polymers 0.000 claims 9
- 102000035195 Peptidases Human genes 0.000 claims 7
- 108091005804 Peptidases Proteins 0.000 claims 7
- 239000004365 Protease Substances 0.000 claims 7
- 235000001014 amino acid Nutrition 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 6
- 239000007850 fluorescent dye Substances 0.000 claims 6
- 230000008685 targeting Effects 0.000 claims 6
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 4
- 108010016626 Dipeptides Proteins 0.000 claims 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 4
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 4
- 229960002448 dasatinib Drugs 0.000 claims 4
- 229960002584 gefitinib Drugs 0.000 claims 4
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 230000002285 radioactive effect Effects 0.000 claims 4
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 claims 4
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims 4
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims 4
- 229920000620 organic polymer Polymers 0.000 claims 3
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 claims 2
- CLUOUYPICNCYNF-IPIKRLCPSA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CCCNC(N)=N.OC(=O)[C@@H](N)CC1=CC=CC=C1 CLUOUYPICNCYNF-IPIKRLCPSA-N 0.000 claims 2
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims 2
- 102000004225 Cathepsin B Human genes 0.000 claims 2
- 108090000712 Cathepsin B Proteins 0.000 claims 2
- 102000005927 Cysteine Proteases Human genes 0.000 claims 2
- 108010005843 Cysteine Proteases Proteins 0.000 claims 2
- 102000012479 Serine Proteases Human genes 0.000 claims 2
- 108010022999 Serine Proteases Proteins 0.000 claims 2
- 102000004142 Trypsin Human genes 0.000 claims 2
- 108090000631 Trypsin Proteins 0.000 claims 2
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000007062 hydrolysis Effects 0.000 claims 2
- 238000006460 hydrolysis reaction Methods 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 239000000377 silicon dioxide Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 239000012588 trypsin Substances 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 1
- 230000001588 bifunctional effect Effects 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462004738P | 2014-05-29 | 2014-05-29 | |
| US62/004,738 | 2014-05-29 | ||
| US201462094923P | 2014-12-19 | 2014-12-19 | |
| US62/094,923 | 2014-12-19 | ||
| PCT/US2015/032565 WO2015183882A1 (en) | 2014-05-29 | 2015-05-27 | Nanoparticle drug conjugates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017521371A JP2017521371A (ja) | 2017-08-03 |
| JP2017521371A5 true JP2017521371A5 (enExample) | 2019-01-10 |
| JP6573633B2 JP6573633B2 (ja) | 2019-09-11 |
Family
ID=53284649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016569722A Active JP6573633B2 (ja) | 2014-05-29 | 2015-05-27 | ナノ粒子薬物コンジュゲート |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10111963B2 (enExample) |
| EP (2) | EP3148591B1 (enExample) |
| JP (1) | JP6573633B2 (enExample) |
| KR (2) | KR102051038B1 (enExample) |
| CN (2) | CN113082225A (enExample) |
| AU (1) | AU2015267200B2 (enExample) |
| BR (1) | BR112016027624A8 (enExample) |
| CA (2) | CA3201974C (enExample) |
| DK (1) | DK3148591T3 (enExample) |
| ES (1) | ES2788865T3 (enExample) |
| PL (1) | PL3148591T3 (enExample) |
| RU (1) | RU2016144055A (enExample) |
| WO (1) | WO2015183882A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3223013T3 (en) | 2009-07-02 | 2019-04-15 | Sloan Kettering Inst Cancer Res | FLUORESCING SILICA-BASED NANOPARTICLES |
| US12161734B2 (en) | 2009-07-02 | 2024-12-10 | Sloan-Kettering Institute For Cancer Research | Multimodal silica-based nanoparticles |
| CA2900363C (en) | 2013-03-15 | 2023-10-10 | Sloan-Kettering Institute For Cancer Research | Multimodal silica-based nanoparticles |
| US10986997B2 (en) | 2013-12-31 | 2021-04-27 | Memorial Sloan Kettering Cancer Center | Systems, methods, and apparatus for multichannel imaging of fluorescent sources in real time |
| EP3148591B1 (en) | 2014-05-29 | 2020-03-11 | Memorial Sloan Kettering Cancer Center | Nanoparticle drug conjugates |
| RU2017122621A (ru) | 2014-12-15 | 2019-01-17 | Мемориал Слоун Кеттеринг Кэнсер Сентр | Циклические пептиды с улучшенной селективностью связывания с нервами, наночастицы, связанные с указанными циклическими пептидами, и их применение для визуализации нервной ткани in vivo в реальном времени |
| US10736972B2 (en) | 2015-05-29 | 2020-08-11 | Memorial Sloan Kettering Cancer Center | Methods of treatment using ultrasmall nanoparticles to induce cell death of nutrient-deprived cancer cells via ferroptosis |
| WO2017189961A1 (en) | 2016-04-29 | 2017-11-02 | Memorial Sloan Kettering Cancer Center | Compositions and methods for targeted particle penetration, distribution, and response in malignant brain tumors |
| BR112019000143A2 (pt) | 2016-07-07 | 2019-04-16 | Memorial Sloan Kettering Cancer Center | sistemas de imagem e métodos para radiogenomia de câncer conduzido por partícula, baseado no conhecimento e preditivo |
| WO2018217528A1 (en) * | 2017-05-25 | 2018-11-29 | Memorial Sloan Kettering Cancer Center | Ultrasmall nanoparticles labeled with zirconium-89 and methods thereof |
| EP3642599B1 (en) | 2017-06-23 | 2025-01-08 | Memorial Sloan-Kettering Cancer Center | Method of imaging in vivo tissues using nanoparticles comprising a reference dye and a sensor dye. |
| RU2679075C1 (ru) * | 2017-11-09 | 2019-02-05 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Конъюгат люминесцентных наночастиц диоксида кремния с рекомбинантными однодоменными нано - моноантителами C7b ламы, способными специфически взаимодействовать с рекомбинантным белком HER2/neu - аналогом природного рецептора эпидермального фактора роста EGFR/ERBB клеток человека |
| US20200383943A1 (en) | 2017-12-04 | 2020-12-10 | Memorial Sloan Kettering Cancer Center | Methods of cancer treatment via regulated ferroptosis |
| US12201956B2 (en) | 2018-10-16 | 2025-01-21 | Pharma In Silica Laboratories Inc. | Tunable process for silica capsules/spheres preparation and their use |
| GB201904336D0 (en) * | 2019-03-28 | 2019-05-15 | Sisaf Ltd | A delivery system |
| US20230381349A1 (en) * | 2020-10-06 | 2023-11-30 | Washington University | Methods and compositions for imaging and treating cancer |
| WO2022093800A2 (en) | 2020-10-27 | 2022-05-05 | Elucida Oncology, Inc. | Carrier particle-drug conjugates, self-immolative linkers, and uses thereof |
| CN112168977A (zh) * | 2020-10-27 | 2021-01-05 | 西南大学 | 转铁蛋白修饰的二氧化硅荷载白藜芦醇及制备方法和应用 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3870791A (en) | 1972-04-24 | 1975-03-11 | Heskel M Haddad | Solid state ophthalmic medication delivery method |
| US3867519A (en) | 1972-04-27 | 1975-02-18 | Alza Corp | Bioerodible drug delivery device |
| US4051842A (en) | 1975-09-15 | 1977-10-04 | International Medical Corporation | Electrode and interfacing pad for electrical physiological systems |
| DE2626348C3 (de) | 1976-06-11 | 1980-01-31 | Siemens Ag, 1000 Berlin Und 8000 Muenchen | Implantierbare Dosiereinrichtung |
| US4136177A (en) | 1977-01-31 | 1979-01-23 | American Home Products Corp. | Xanthan gum therapeutic compositions |
| US4255415A (en) | 1978-11-22 | 1981-03-10 | Schering Corporation | Polyvinyl alcohol ophthalmic gel |
| US4383529A (en) | 1980-11-03 | 1983-05-17 | Wescor, Inc. | Iontophoretic electrode device, method and gel insert |
| US4931279A (en) | 1985-08-16 | 1990-06-05 | Bausch & Lomb Incorporated | Sustained release formulation containing an ion-exchange resin |
| US4688506A (en) | 1985-09-03 | 1987-08-25 | Breems Martinus Van | Boat sail control system |
| US4788603A (en) | 1985-10-19 | 1988-11-29 | Fuji Photo Film Co., Ltd. | Camera for sequentially photographing a subject using a reference optical system and a telescopic optical system |
| US4812409A (en) | 1986-01-31 | 1989-03-14 | Eastman Kodak Company | Hydrolyzable fluorescent substrates and analytical determinations using same |
| US4713224A (en) | 1986-03-31 | 1987-12-15 | The Boc Group, Inc. | One-step process for purifying an inert gas |
| US4810636A (en) | 1986-12-09 | 1989-03-07 | Miles Inc. | Chromogenic acridinone enzyme substrates |
| US4774339A (en) | 1987-08-10 | 1988-09-27 | Molecular Probes, Inc. | Chemically reactive dipyrrometheneboron difluoride dyes |
| US5433896A (en) | 1994-05-20 | 1995-07-18 | Molecular Probes, Inc. | Dibenzopyrrometheneboron difluoride dyes |
| US5274113A (en) | 1991-11-01 | 1993-12-28 | Molecular Probes, Inc. | Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates |
| US5248782A (en) | 1990-12-18 | 1993-09-28 | Molecular Probes, Inc. | Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes |
| US5187288A (en) | 1991-05-22 | 1993-02-16 | Molecular Probes, Inc. | Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| US5830912A (en) | 1996-11-15 | 1998-11-03 | Molecular Probes, Inc. | Derivatives of 6,8-difluoro-7-hydroxycoumarin |
| GB2330907A (en) | 1997-10-28 | 1999-05-05 | Applied Imaging Int Ltd | A karyotyper and methods for producing karyotypes |
| ATE239801T1 (de) | 1998-01-22 | 2003-05-15 | Luminex Corp | Mikropartikel mit multiplen fluoreszenz-signalen |
| US6254852B1 (en) | 1999-07-16 | 2001-07-03 | Dupont Pharmaceuticals Company | Porous inorganic targeted ultrasound contrast agents |
| US7279150B2 (en) | 2002-01-24 | 2007-10-09 | Barnes-Jewish Hospital | Chelating agents with lipophilic carriers |
| WO2003066066A1 (en) | 2002-02-01 | 2003-08-14 | Vanderbilt University | Targeted drug delivery methods |
| US8620410B2 (en) | 2002-03-12 | 2013-12-31 | Beth Israel Deaconess Medical Center | Multi-channel medical imaging system |
| US20040101822A1 (en) | 2002-11-26 | 2004-05-27 | Ulrich Wiesner | Fluorescent silica-based nanoparticles |
| WO2004108902A2 (en) | 2003-06-04 | 2004-12-16 | Visen Medical, Inc. | Biocompatible fluorescent silicon nanoparticles |
| WO2006042233A1 (en) | 2004-10-08 | 2006-04-20 | The Cleveland Clinic Foundation | Medical imaging using quantum dots |
| US7653427B2 (en) | 2004-11-12 | 2010-01-26 | Intra-Medical Imaging LLC | Method and instrument for minimally invasive sentinel lymph node location and biopsy |
| WO2006099445A2 (en) * | 2005-03-14 | 2006-09-21 | Massachusetts Institute Of Technology | Nanocells for diagnosis and treatment of diseases and disorders |
| AU2006339072A1 (en) | 2005-03-14 | 2007-10-25 | Board Of Regents Of The University Of Texas System | Bioactive FUS1 peptides and nanoparticle-polypeptide complexes |
| US8084001B2 (en) | 2005-05-02 | 2011-12-27 | Cornell Research Foundation, Inc. | Photoluminescent silica-based sensors and methods of use |
| US7601355B2 (en) | 2005-06-01 | 2009-10-13 | Northwestern University | Compositions and methods for altering immune function |
| JP2008546804A (ja) | 2005-06-24 | 2008-12-25 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | 造影剤として用いるためのリガンドの放射性標識ペグ化 |
| FR2888753B1 (fr) | 2005-07-21 | 2008-04-04 | Commissariat Energie Atomique | Vecteur cible avec fonction d'imagerie activable |
| WO2007136413A2 (en) * | 2005-12-22 | 2007-11-29 | Visen Medical, Inc. | Biocompatible fluorescent metal oxide nanoparticles |
| WO2008044138A1 (en) | 2006-10-12 | 2008-04-17 | Syddansk Universitet | Optical nanosensor for detection of reactive oxygen species |
| WO2008049118A2 (en) | 2006-10-19 | 2008-04-24 | The General Hospital Corporation | Apparatus and method for obtaining and providing imaging information associated with at least one portion of a sample and effecting such portion(s) |
| US7902332B2 (en) | 2006-11-30 | 2011-03-08 | General Electric Company | Fluorine-labeled compounds |
| WO2008073856A2 (en) | 2006-12-08 | 2008-06-19 | Massachusetts Institute Of Technology | Delivery of nanoparticles and/or agents to cells |
| US8239008B2 (en) | 2007-04-13 | 2012-08-07 | Ethicon Endo-Surgery, Inc. | Sentinel node identification using fluorescent nanoparticles |
| EP1995327A1 (en) | 2007-05-21 | 2008-11-26 | Humboldt Universität zu Berlin | Probe for detecting a particular nucleic acid sequence |
| WO2009029870A2 (en) | 2007-08-31 | 2009-03-05 | Hybrid Silica Technologies, Inc. | Peg-coated core-shell silica nanoparticles and methods of manufacture and use |
| DE102007052517A1 (de) | 2007-10-29 | 2009-04-30 | Autoimmun Diagnostika Gmbh | ELISPOT-Verfahren mit zwei Filtersystemen |
| WO2009064964A2 (en) | 2007-11-15 | 2009-05-22 | The University Of California | Switchable nano-vehicle delivery systems, and methods for making and using them |
| WO2009085218A1 (en) | 2007-12-21 | 2009-07-09 | President And Fellows Of Harvard College | Sub-diffraction limit image resolution in three dimensions |
| WO2010091294A2 (en) | 2009-02-05 | 2010-08-12 | The Regents Of The University Of California | New targeted antimicrobial moieties |
| DK3223013T3 (en) * | 2009-07-02 | 2019-04-15 | Sloan Kettering Inst Cancer Res | FLUORESCING SILICA-BASED NANOPARTICLES |
| IN2012DN05099A (enExample) * | 2009-12-16 | 2015-10-09 | Brigham & Womens Hospital | |
| SI2528625T1 (sl) * | 2010-04-15 | 2013-11-29 | Spirogen Sarl | Pirolobenzodiazepini in njihovi konjugati |
| US10732115B2 (en) | 2012-06-22 | 2020-08-04 | Cornell University | Mesoporous oxide nanoparticles and methods of making and using same |
| US9695133B2 (en) | 2012-07-13 | 2017-07-04 | The Trustees Of Columbia University In The City Of New York | Quinazolinone-based oncogenic-RAS-selective lethal compounds and their use |
| CN112587671A (zh) * | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| CA2900363C (en) | 2013-03-15 | 2023-10-10 | Sloan-Kettering Institute For Cancer Research | Multimodal silica-based nanoparticles |
| EP3148591B1 (en) | 2014-05-29 | 2020-03-11 | Memorial Sloan Kettering Cancer Center | Nanoparticle drug conjugates |
| US10736972B2 (en) | 2015-05-29 | 2020-08-11 | Memorial Sloan Kettering Cancer Center | Methods of treatment using ultrasmall nanoparticles to induce cell death of nutrient-deprived cancer cells via ferroptosis |
| EP3642599B1 (en) | 2017-06-23 | 2025-01-08 | Memorial Sloan-Kettering Cancer Center | Method of imaging in vivo tissues using nanoparticles comprising a reference dye and a sensor dye. |
-
2015
- 2015-05-27 EP EP15727248.5A patent/EP3148591B1/en active Active
- 2015-05-27 KR KR1020167035356A patent/KR102051038B1/ko active Active
- 2015-05-27 CN CN202110399761.9A patent/CN113082225A/zh active Pending
- 2015-05-27 US US14/722,307 patent/US10111963B2/en active Active
- 2015-05-27 KR KR1020197034930A patent/KR102231672B1/ko active Active
- 2015-05-27 PL PL15727248T patent/PL3148591T3/pl unknown
- 2015-05-27 CA CA3201974A patent/CA3201974C/en active Active
- 2015-05-27 BR BR112016027624A patent/BR112016027624A8/pt not_active Application Discontinuation
- 2015-05-27 ES ES15727248T patent/ES2788865T3/es active Active
- 2015-05-27 CA CA2947895A patent/CA2947895C/en active Active
- 2015-05-27 AU AU2015267200A patent/AU2015267200B2/en active Active
- 2015-05-27 DK DK15727248.5T patent/DK3148591T3/da active
- 2015-05-27 RU RU2016144055A patent/RU2016144055A/ru not_active Application Discontinuation
- 2015-05-27 EP EP20152240.6A patent/EP3693026A1/en active Pending
- 2015-05-27 CN CN201580029280.1A patent/CN106659797B/zh active Active
- 2015-05-27 WO PCT/US2015/032565 patent/WO2015183882A1/en not_active Ceased
- 2015-05-27 JP JP2016569722A patent/JP6573633B2/ja active Active
-
2018
- 2018-09-21 US US16/137,709 patent/US10485881B2/en active Active
-
2019
- 2019-10-15 US US16/653,490 patent/US20200289668A1/en not_active Abandoned
-
2024
- 2024-10-10 US US18/911,705 patent/US20250269054A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017521371A5 (enExample) | ||
| Gyimesi et al. | Transporter-mediated drug delivery | |
| Hu et al. | Advances in peptide functionalization on mesoporous silica nanoparticles for controlled drug release | |
| Sapra et al. | Designer peptide and protein dendrimers: a cross-sectional analysis | |
| Chang et al. | Smart linkers in polymer–drug conjugates for tumor-targeted delivery | |
| ES2383901T3 (es) | Polipéptidos de aprotinina para transportar un compuesto a través de la barrera sangre-cerebro | |
| ES2627822T3 (es) | Péptidos de penetración celular para administración intracelular de moléculas | |
| Cheng et al. | Activable cell-penetrating peptide conjugated prodrug for tumor targeted drug delivery | |
| CN103402545B (zh) | 疏水性经修饰肽及其在肝特异性靶向中的用途 | |
| KR102051038B1 (ko) | 나노입자 약물 컨쥬게이트 | |
| US9216228B2 (en) | Receptor and antigen targeted prodrug | |
| Yun et al. | Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery | |
| Zhang et al. | Enhanced cellular entry and efficacy of tat conjugates by rational design of the auxiliary segment | |
| Wang et al. | Peptide-mediated nanocarriers for targeted drug delivery: developments and strategies | |
| AU2001275525B2 (en) | Tripeptide prodrug compounds | |
| ES2269160T3 (es) | Procedimiento para la preparacion de una formulacion medicamentosa inyectable. | |
| ES2269397T3 (es) | Sistemas de ligando terapeuticos y de diagnostico que comprenden propiedades de union a moleculas de transporte y medicamentos que los contienen. | |
| JP2009500431A5 (enExample) | ||
| Jadhav et al. | Peptide–drug conjugates as next-generation therapeutics: exploring the potential and clinical progress | |
| Guan et al. | Peptide-targeted polyglutamic acid doxorubicin conjugates for the treatment of αvβ6-positive cancers | |
| Egorova et al. | Smart delivery systems responsive to cathepsin B activity for cancer treatment | |
| CN103080125A (zh) | 用于治疗性结合物的短且含d氨基酸的多肽及其使用 | |
| WO2019061561A1 (zh) | 一种药物递送体系及其制备方法与应用 | |
| JP2012521201A5 (enExample) | ||
| Acar et al. | Cathepsin-mediated cleavage of peptides from peptide amphiphiles leads to enhanced intracellular peptide accumulation |